PANCREATIC DUCTAL ADENOCARCINOMA

This study tests a more thorough surgery technique for pancreatic head cancer, called total mesopancreas excision. The goal is to remove more tissue around the tumor to lower the chance of cancer coming back. Researchers will follow 90 adults for 24 months to see if this approach…

This early-phase study tests a new drug called DR-0202 in people with advanced solid tumors (like breast, lung, or pancreatic cancer) that have not responded to at least two prior treatments. The main goals are to check the drug's safety and find the best dose. About 96 participa…

This study tests an experimental drug called AZD4360 in adults with advanced solid tumors, including stomach, gastroesophageal junction, bile duct, and pancreatic cancers that have not responded to prior treatments. The main goals are to find a safe dose and check if the drug can…

This study tests a new way of giving chemotherapy to people with metastatic pancreatic cancer. Instead of using one drug combination, patients will receive two different standard chemotherapy regimens (NALIRIFOX and GnP) in alternating months. The goal is to see if this approach …

This study tests a new treatment that delivers a powerful, short-range radioactive particle directly to cancer cells that have a protein called FAP on their surface. The therapy is given in two steps: first a low-dose imaging version to see if the tumor takes up the drug, then a …

This study aims to see if MRI scans can find tiny liver tumors in people with pancreatic cancer that standard CT scans often miss. About 120 adults with newly diagnosed pancreatic cancer will get both a CT and an MRI. If MRI proves better at detecting these hidden metastases, it …

This study looks at whether genetic information from tumors can help doctors choose the best treatment for pancreatic cancer. About 200 people with early or locally advanced pancreatic cancer will give blood and tissue samples for genetic testing. Researchers want to see if they …

This study looks at whether a simple blood test that measures tumor DNA (ctDNA) can tell doctors within weeks if chemotherapy is shrinking a patient's pancreatic cancer. Currently, doctors wait about 8 weeks for a scan to see if treatment is working. The goal is to see if the blo…

This early-stage study tests a new substance called RAD301 in 9 people—some healthy, some with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how RAD301 moves through the body and how much radiation reaches organs and tumors, and to che…